Abstract 2162P
Background
There is limited data on the quality of cancer information provided by ChatGPT and other artificial intelligence systems. In this study, we aimed to compare the accuracy of information about cancer pain provided by chatbots (chatGPT, perplexity, and chatsonic) based on the questions and answers contained in the the European Medical Oncology Association (ESMO) Patient Guide about cancer pain.
Methods
Twenty questions were selected from the questions available in the ESMO Patient Guide Cancer Pain. Medical oncologists with more than 10 years of experience compared responses from chatbots (ChatGPT, Perplexity, and Chatsonic) with the ESMO patient guide. The primary evaluation criteria for the quality of the responses were accuracy, patient readability, and stability of response. The accuracy of responses was evaluated using a three-point scale: 1 for accuracy, 2 for a mixture of accurate and incorrect or outdated data, and 3 for wholly inaccurate. The Flesch-Kincaid readability (FKr) grade was used to measure readability. Stability of responses was evaluated whether the model’s accuracy is consistent across different answers to the same question.
Results
Chatbots were more difficult to read than the ESMO patient guideline (FKr= 9.6 vs. 12.8, p= 0.072). Among the chatbots, perplexity had the easiest readability (FKr= 11.2). In the accuracy evaluation, the percentage of overall agreement for accuracy was 100% for ESMO answers and 96% for ChatGPT outputs for questions (k= 0.03, standard error= 0.08). Among the chatbots, the most accurate information was obtained with chatGPT.
Table: 2162P
Comparison of ESMO and chatbots in terms of readibility and accuracy
ESMO | Chatbots | ||||
ChatGPT | Perplexity | Chatsonic | p-value | ||
Readibility (FKr grade) | 9.6 Easily understood | 13.4 Difficult to read | 11.2 Fairly difficult to read | 13.9 Difficult to read | 0.072 |
Accuracy | %100 | %96 | %86 | % 90 | 0.037 |
Conclusions
The results suggest that ChatGPT provides more accurate information about cancer pain compared with other chatbots.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gazi University Ethic Commitee.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2194P - Prospective observational study of physical activity measurement using wearable device as an alternative to ECOG PS in patients with advanced lung cancer
Presenter: Kentaro Ito
Session: Poster session 07
Resources:
Abstract
2195P - Targeted gene editing with CRISPR for the treatment of pleural mesothelioma
Presenter: Rodrigo Dominic Cerqueda
Session: Poster session 07
2196P - PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT
Presenter: Daniel C. Christoph
Session: Poster session 07
2197P - Prognostic value of 18F-FDG-PET for patients with malignant pleural mesothelioma treated with double immunotherapy
Presenter: Solfrid Thunold
Session: Poster session 07
2198P - Clinicopathologic characteristics and outcomes to immune checkpoint inhibitor therapy in patients with HER2-altered metastatic non-small cell lung cancer
Presenter: Maisam Makarem
Session: Poster session 07
2199P - Immunohistochemical identification of clinical subtypes and potential therapeutic vulnerabilities of lung carcinoids based on multi-omic analysis
Presenter: Jules Derks
Session: Poster session 07
2200P - Spatiotemporal distribution of mediastinal neoplasms: A multi-center, hospital-based, systematic analysis
Presenter: Yu Jiang
Session: Poster session 07
2201P - Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies
Presenter: Sabine Schmid
Session: Poster session 07
2202P - Large cell neuroendocrine carcinoma (LCNEC) subtyping based on NEUROD1, ASCL1, POU2F3 and YAP1 expression
Presenter: Frank Heijboer
Session: Poster session 07
2203P - Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma
Presenter: Mario Occhipinti
Session: Poster session 07